Fpk1 regulates Cdr1 expression and ergosterol homeostasis in <i>Nakaseomyces glabratus</i> ( <i>Candida glabrata</i> ) during azole exposure.

<jats:p> Azoles remain the most common antifungal therapy worldwide. However, <jats:italic>Nakaseomyces glabratus</jats:italic> (previously named <jats:italic>Candida glabrata</jats:italic> ) has a high intrinsic tolerance against azole drugs. The organism can also accrue additional chromosomal mutations to elevate its resistant level during treatment. These genetic alterations often result in overexpression of the ABC transmembrane transporter Cdr1, which has been shown to directly transport drugs out of the fungal cells. Another resistant mechanism is the upregulation of the ergosterol biosynthesis pathway, which is the direct target of azoles. Although the mechanisms of azole resistance in <jats:italic>N. glabratus</jats:italic> are well defined, knowledge of their regulation remains limited. Here, we show that the protein kinase Fpk1 is required for optimal azole response <jats:italic>in vitro</jats:italic> and in an <jats:italic>in vivo</jats:italic> mouse infection model. Loss of Fpk1 gene or its kinase function significantly enhances azole sensitivity in both azole-susceptible and -resistant clinical isolates. Fpk1 function is required for optimal expression of Cdr1 upon azole challenge. It also influences the intracellular trafficking of ergosterol, without affecting its biosynthesis. Together, our data demonstrates the important role of Fpk1 function in the <jats:italic>N. glabratus</jats:italic> azole response and characterizes it as a new regulator of the efflux pump and ergosterol biosynthesis pathways. </jats:p>